Ovarian Cancer Trial, Recruiting NCT01689584 Sponsor: Institut Curie Condition: Ovarian Cancer
Back to Ovarian Cancer

Ovarian Cancer Trial, Recruiting

NCT01689584
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been found to carry a specific genetic variant (a change in a gene) through testing done by one of the laboratories in the GGC-Unicancer network, where that variant has been classified as class 3, class 4, or hypomorphic class 5, and has been selected for study by a national expert group for that gene (confirm with trial site)
  • People who are 18 years of age or older
  • People who have signed the written informed consent form for "index cases" (the person whose genetic result started the study)
  • Family members of an index case who have cancer
  • Family members of an index case who do not have cancer, chosen by the researchers based on how closely related they are to the index case
  • For class 4 and hypomorphic class 5 variants: family members who are currently being tested or who have already received a test result for the genetic variant as part of their regular medical care
  • Family members who are 18 years of age or older and have signed the informed consent form for "selected relatives"

Who may not be able to join:

  • People who are under 18 years of age
  • People who are in prison or under legal guardianship or curatorship
  • People who have not signed the required written informed consent form

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Chrystelle COLAS, MD, PhD, Institut Curie

Phone: 33172389367

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Institut Curie
Registry
ClinicalTrials.gov
Start date
2 July 2012
Est. completion
2 July 2037

Where this trial is recruiting

🇫🇷 France Guadeloupe Martinique New Caledonia Reunion

Primary endpoints

Perform the co-segregation analysis of the selected VUS (class 3) or likely pathogenic variant (class 4) in the families.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov